Odyssey Therapeutics, Inc.
ODTXCIK 0001882782 · Biological Products, (No Diagnostic Substances) · Nasdaq
Revenue (TTM)
—
Q1 Jun 2026
Net Income (TTM)
—
Q1 Jun 2026
EPS Diluted (TTM)
—
Q1 Jun 2026
Gross Margin
—
Q1 Jun 2026
Operating Margin
—
Q1 Jun 2026
Net Margin
—
Q1 Jun 2026
Free Cash Flow (TTM)
—
Q1 Jun 2026
Cash
$35.72M
Q1 Jun 2026
Total Debt
—
Q1 Jun 2026
Shares Outstanding
48.03M sh
Q1 Jun 2026
Latest news
All news →-
High Positive
Odyssey Therapeutics (ODTX) Reports OD-001 POC, Raises $464M
Clinical-stage biotech achieves proof-of-concept for ulcerative colitis drug and closes IPO plus private placement.